Overview

Mass Balance and Biotransformation of [14C]HSK7653 in Human

Status:
Recruiting
Trial end date:
2021-03-30
Target enrollment:
Participant gender:
Summary
A single-center, single-dose, non-randomized, open-label design.
Phase:
Phase 1
Details
Lead Sponsor:
Sichuan Haisco Pharmaceutical Group Co., Ltd
Sichuan Haisco Pharmaceutical Group Co., Ltd.
Collaborators:
First Affiliated Hospital of Suzhou Medical College
The First Affiliated Hospital of Suzhou University